Vaxil BioTherapeutics
Developing Cancer and Tuberculosis Vaccines
Company Overview
Snapshot
Founded in February 2007 by Lior Carmon, Vaxil BioTherapeutics operates with 1–10 employees. The company has raised a total of $6.35M across 4 funding rounds from 2 investors. In May 2024, Vaxil Bio entered into a Letter of Intent with Green Data regarding a proposed reverse takeover.
Business overview
Vaxil BioTherapeutics is a clinical-stage company focused on developing immunotherapeutic products, including long peptide vaccines and antibodies, to treat cancer and infectious diseases. Its core technology, VaxHit, utilizes signal peptide domains in selected targets as core antigens. The company's lead product, ImMucin, has received orphan drug designation for multiple myeloma and has completed Phase 1/2 clinical trials. Vaxil also develops anti-MUC1 SP antibodies (SPmAb-2.1 and SPmAb-6) and a vaccine against mycobacterium tuberculosis, MTBuVax, currently in preclinical studies. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Biotechnology, serving markets in Israel, Canada, and the United States.
Strategic signal
In May 2024, Vaxil Bio announced its entry into a Letter of Intent with Green Data for a proposed reverse takeover. This strategic move signals a potential restructuring or pivot in the company's corporate strategy, which could impact its future direction and investor outlook.
Log in to access full profile ›Company Intelligence Q&A
- When did Vaxil BioTherapeutics go public?
- Vaxil BioTherapeutics went public on TASE in March 2016.
- What is the status of Vaxil BioTherapeutics' lead product, ImMucin?
- ImMucin has received EMA and FDA orphan drug designation for multiple myeloma and has successfully completed a phase 1/2 clinical trial. Vaxil is also performing an additional phase 1/2 study with ImMucin in metastatic breast cancer patients.
- What significant corporate event did Vaxil BioTherapeutics announce in May 2024?
- In May 2024, Vaxil Bio entered into a Letter of Intent with Green Data regarding a proposed reverse takeover.
- What is Vaxil BioTherapeutics' total funding?
- Vaxil BioTherapeutics has raised a total of $6.35M across 4 funding rounds.